Neurotez is focused on developing innovative biotechnology solutions aimed at addressing brain disorders, particularly Alzheimer's disease and other neurodegenerative conditions. The company employs a comprehensive approach that integrates biochemical, molecular, and cell biology techniques, alongside in vivo models, to screen and identify potential therapeutic candidates. Their research emphasizes the intricate relationship between metabolic pathways and the pathology of Alzheimer's disease, supported by genetic and epidemiological studies. This foundational understanding informs their mission to create safe and effective central nervous system (CNS) drugs, ultimately improving patient outcomes.

The company's pipeline includes promising candidates such as Memtin, a biologic asset poised to enter Phase 2 clinical trials for Alzheimer's patients, with the potential for accelerated approval following positive trial results. Additionally, Neurotez is developing small peptides, NT1 and NT2, which target specific protein interactions that may serve as preventative therapies for early-onset familial Alzheimer's disease. To facilitate drug discovery, Neurotez has established two proprietary screening platforms—Screen A and Screen B—designed to identify new molecular entities that intersect with metabolic and neurodegenerative pathways, as well as to discover binding partners for specific protein targets.

United States

Neurotez Inc. is a biotechnology company focused on developing a Leptin product as a hormone replacement therapy for Alzheimer's disease. Their mission is to become world leaders in biotechnology, utilizing an integrated platform from discovery to proof of concept clinical trials for CNS drugs.

Neurotez

Company Details